[1] |
苗恒,陶勇,黎晓新. 重视眼部移植物抗宿主病的诊断和治疗[J]. 中华眼科医学杂志(电子版),2014,4(1):1-6.
|
[2] |
Ferrara JL, Levine JE, Reddy P, et al. Graft-versus-host disease[J]. The Lancet, 2009, 373(9674): 1550-1561.
|
[3] |
Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report[J]. Biol Blood Marrow Transplant, 2005, 11(12): 945-956.
|
[4] |
Zeiser R, Blazar BR. Acute graft-versus-host disease——biologic process, prevention, and therapy[J]. N Engl J Med, 2017, 377(22): 2167-2179.
|
[5] |
Malard F, Holler E, Sandmaier BM, et al. Acute graft-versus-host disease[J]. Nat Rev Dis Primers, 2023, 9(1): 27.
|
[6] |
Baumrin E, Loren AW, Falk SJ, et al. Chronic graft-versus-host disease. Part I: Epidemiology, pathogenesis, and clinical manifestations[J]. J Am Acad Dermatol, 2024, 90(1): 1-16.
|
[7] |
Liu YC, Gau JP, Lin PY, et al. Conjunctival acute graft-versus-host disease in adult patients receiving allogeneic hematopoietic stem cell transplantation: a cohort study[J]. PLoS One, 2016, 11(11): e167129.
|
[8] |
Hirst LW, Jabs DA, Tutschka PJ, et al. The eye in bone marrow transplantation: Ⅰ. clinical study[J]. Arch Ophthalmol, 1983, 101(4): 580-584.
|
[9] |
Saito T, Shinagawa K, Takenaka K, et al. Ocular manifestation of acute graft-versus-host disease after allogeneic peripheral blood stem cell transplantation[J]. Int J Hematol, 2002, 75(3): 332-334.
|
[10] |
Uchino M, Ogawa Y, Kawai M, et al. Ocular complications in a child with acute graft-versus-host disease following cord blood stem cell transplantation: therapeutic challenges[J]. Acta Ophthalmol Scand, 2006, 84(4): 545-548.
|
[11] |
Hayashi S, Shimizu E, Uchino M, et al. The overlap syndrome: a case report of chronic graft-versus-host disease after the development of a pseudomembrane[J]. Cornea, 2021, 40(9): 1188-1192.
|
[12] |
Soleimani M, Mahdavi SP, Cheraqpour K, et al. Ocular graft-versus-host disease (oGVHD): From A to Z[J]. Surv Ophthalmol, 2023, 68(4): 697-712.
|
[13] |
Robinson MR, Lee SS, Rubin BI, et al. Topical corticosteroid therapy for cicatricial conjunctivitis associated with chronic graft-versus-host disease[J]. Bone Marrow Transplant, 2004, 33(10): 1031-1035.
|
[14] |
Nair S, Vanathi M, Mukhija R, et al. Update on ocular graft-versus-host disease[J]. Indian J Ophthalmol, 2021, 69(5): 1038-1050.
|
[15] |
Kim SK, Couriel D, Ghosh S, et al. Ocular graft vs. host disease experience from MD Anderson Cancer Center: Newly described clinical spectrum and new approach to the management of stage III and IV ocular GVHD[J]. Biol Blood Marrow Transplant, 2006, 12(2): 49-50.
|
[16] |
Ogawa Y, Yamazaki K, Kuwana M, et al. A significant role of stromal fibroblasts in rapidly progressive dry eye in patients with chronic GVHD[J]. Invest Ophthalmol Vis Sci, 2001, 42(1): 111-119.
|
[17] |
Zhao W, Yang J, Liao Y, et al. Comparable meibomian gland changes in patients with and without ocular graft-versus-host disease after hematopoietic stem cell transplantation[J]. Ocul Surf, 2022, 25: 1-7.
|
[18] |
Choi W, Ha JY, Li Y, et al. Comparison of the meibomian gland dysfunction in patients with chronic ocular graft-versus-host disease and Sjögren′s syndrome[J]. Int J Ophthalmol, 2019, 12(3): 393-400.
|
[19] |
Engel LA, Wittig S, Bock F, et al. Meibography and meibomian gland measurements in ocular graft-versus-host disease[J]. Bone Marrow Transplant, 2015, 50(7): 961-967.
|
[20] |
Hettinga YM, Verdonck LF, Fijnheer R, et al. Anterior uveitis: a manifestation of graft-versus-host disease[J]. Ophthalmology, 2007, 114(4): 794-797.
|
[21] |
Lin CY, Chien HJ. Acute exacerbation of ocular graft-versus-host disease and anterior uveitis after COVID-19 vaccination[J]. BMC Ophthalmol, 2023, 23(1): 360.
|
[22] |
Kaiserman I, Or R. Laser photocoagulation for central serous retinopathy associated with graft-versus-host disease[J]. Ocul Immunol Inflamm, 2005, 13(2-3): 249-256.
|
[23] |
Xu Y, Wang YM, Sun ZT, et al. Corneal perforation associated with ocular graft-versus-host disease[J]. Front Oncol, 2022, 12: 962250.
|
[24] |
Inagaki E, Ogawa Y, Matsumoto Y, et al. Four cases of corneal perforation in patients with chronic graft-versus-host disease[J]. Mol Vis, 2011, 17: 598-606.
|
[25] |
Balaram M, Rashid S, Dana R. Chronic ocular surface disease after allogeneic bone marrow transplantation[J]. Ocul Surf, 2005, 3(4): 203-211.
|
[26] |
Tabbara KF, Al-Ghamdi A, Al-Mohareb F, et al. Ocular Findings after Allogeneic Hematopoietic Stem Cell Transplantation[J]. Ophthalmology, 2009, 116(9): 1624-1629.
|
[27] |
Sinha S, Singh RB, Dohlman TH, et al. Prevalence of persistent corneal epithelial defects in chronic ocular graft-versus-host disease[J]. Am J Ophthalmol, 2020, 218: 296-303.
|
[28] |
Sepulveda-Beltran PA, Carletti P, Banda V, et al. Infectious and noninfectious corneal ulcers in ocular graft-versus-host disease: epidemiology, clinical characteristics, and outcomes[J]. Am J Ophthalmol, 2024, 257: 236-246.
|
[29] |
Ogawa Y, Shimmura S, Kawakita T, et al. Epithelial mesenchymal transition in human ocular chronic graft-versus-host disease[J]. Am J Pathol, 2009, 175(6): 2372-2381.
|
[30] |
Ogawa Y, Kawakami Y, Tsubota K. Cascade of inflammatory, fibrotic processes, and stress-induced senescence in chronic GVHD-related dry eye disease[J]. Int J Mol Sci, 2021, 22(11): 6114.
|
[31] |
Dietrich-Ntoukas T, Cursiefen C, Westekemper H, et al. Diagnosis and treatment of ocular chronic graft-versus-host disease: report from the German-Austrian-Swiss Consensus Conference on Clinical Practice in chronic GVHD[J]. Cornea, 2012, 31(3): 299-310.
|
[32] |
Doughty MJ, Glavin S. Efficacy of different dry eye treatments with artificial tears or ocular lubricants: a systematic review[J]. Ophthalmic Physiol Opt, 2009, 29(6): 573-583.
|
[33] |
Balaram M, Schaumberg DA, Dana MR. Efficacy and tolerability outcomes after punctal occlusion with silicone plugs in dry eye syndrome[J]. Am J Ophthalmol, 2001, 131(1): 30-36.
|
[34] |
Wang Y, Carreno-Galeano JT, Singh RB, et al. Long-term outcomes of punctal cauterization in the management of ocular surface diseases[J]. Cornea, 2021, 40(2): 168-171.
|
[35] |
Wan KH, Chen LJ, Young AL. Efficacy and safety of topical 0.05% cyclosporine eye drops in the treatment of dry eye syndrome: a systematic review and meta-analysis[J]. Ocul Surf, 2015, 13(3): 213-225.
|
[36] |
Lelli GJ, Musch DC, Gupta A, et al. Ophthalmic cyclosporine use in ocular GVHD[J]. Cornea, 2006, 25(6): 635-638.
|
[37] |
Asena L, Dursun AD. Application of topical 2% cyclosporine A in inflammatory ocular surface diseases[J]. Int Ophthalmol, 2023, 43(11): 3943-3952.
|
[38] |
Barber LD, Pflugfelder SC, Tauber J, et al. Phase Ⅲ safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years[J]. Ophthalmology, 2005, 112(10): 1790-1794.
|
[39] |
Abud TB, Amparo F, Saboo US, et al. A clinical trial comparing the safety and efficacy of topical tacrolimus versus methylprednisolone in ocular graft-versus-host disease[J]. Ophthalmology, 2016, 123(7): 1449-1457.
|
[40] |
Espana EM, Shah S, Santhiago MR, et al. Graft versus host disease: clinical evaluation, diagnosis and management[J]. Graefes Arch Clin Exp Ophthalmol, 2013, 251(5): 1257-1266.
|
[41] |
Jung JW, Lee YJ, Yoon SC, et al. Long-term result of maintenance treatment with tacrolimus ointment in chronic ocular graft-versus-host disease[J]. Am J Ophthalmol, 2015, 159(3): 519-527.
|
[42] |
刘姝婉,赵英涵,马骄,等. 0.05%环孢素A与0.1%他克莫司滴眼液治疗cGVHD相关重度干眼的疗效评价[J]. 中华眼科杂志,2023,59(10):805-813.
|
[43] |
Townley JR, Dana R, Jacobs DS. Keratoconjunctivitis sicca manifestations in ocular graft versus host disease: pathogenesis, presentation, prevention, and treatment[J]. Semin Ophthalmol, 2011, 26(4-5): 251-260.
|
[44] |
Yin J, Kheirkhah A, Dohlman T, et al. Reduced efficacy of low-dose topical steroids in dry eye disease associated with graft-versus-host disease[J]. Am J Ophthalmol, 2018, 190: 17-23.
|
[45] |
Tahmaz V, Gehlsen U, Sauerbier L, et al. Treatment of severe chronic ocular graft-versus-host disease using 100% autologous serum eye drops from a sealed manufacturing system: a retrospective cohort study[J]. Br J Ophthalmol, 2017, 101(3): 322-326.
|
[46] |
Tahmaz V, Wiesen M, Gehlsen U, et al. Detection of systemic immunosuppressants in autologous serum eye drops (ASED) in patients with severe chronic ocular graft versus host disease[J]. Graefes Arch Clin Exp Ophthalmol, 2021, 259(1): 121-128.
|
[47] |
Chaudhary S, Ghimire D, Basu S, et al. Contact lenses in dry eye disease and associated ocular surface disorders[J]. Indian J Ophthalmol, 2023, 71(4): 1142-1153.
|
[48] |
Bligdon SM, Colarusso BA, Ganjei AY, et al. Scleral lens and prosthetic replacement of the ocular surface ecosystem utilization in ocular graft-versus-host disease: a survey study[J]. Clin Ophthalmol, 2021, 15: 4829-4838.
|
[49] |
Peris-Martínez C, Menezo JL, Díaz-Llopis M, et al. Multilayer amniotic membrane transplantation in severe ocular graft versus host disease[J]. Eur J Ophthalmol, 2001, 11(2): 183-186.
|
[50] |
Yin HY, Dhanireddy S, Weisenthal R, et al. Self-retained cryopreserved amniotic membrane in treating acute ocular graft-versus-host-disease (oGVHD)[J]. Am J Ophthalmol Case Rep, 2020, 19: 100761.
|
[51] |
Heath JD, Acheson JF, Schulenburg WE. Penetrating keratoplasty in severe ocular graft versus host disease[J]. Br J Ophthalmol, 1993, 77(8): 525-526.
|
[52] |
Pellegrini M, Bernabei F, Barbato F, et al. Incidence, risk factors and complications of ocular graft-versus-host disease following hematopoietic stem cell transplantation[J]. Am J Ophthalmol, 2021, 227: 25-34.
|
[53] |
Stevenson W, Shikari H, Saboo US, et al. Bilateral corneal ulceration in ocular graft-versus-host disease[J]. Clin Ophthalmol, 2013, 7: 2153-2158.
|
[54] |
Lin X, Cavanagh HD. Ocular manifestations of graft-versus-host disease: 10 years′ experience[J]. Clin Ophthalmol, 2015, 9: 1209-1213.
|
[55] |
Adrean SD, Puklin JE. Perforated corneal ulcer with subsequent endophthalmitis in a patient with graft-versus-host disease[J]. Cornea, 2007, 26(1): 107-108.
|
[56] |
Mohammadpour M, Maleki S, Hashemi H, et al. Recurrent corneal perforation due to chronic graft versus host disease; a clinicopathologic report[J]. J Ophthalmic Vis Res, 2016, 11(1): 108-111.
|
[57] |
Yeh PT, Hou YC, Lin WC, et al. Recurrent corneal perforation and acute calcareous corneal degeneration in chronic graft-versus-host disease[J]. J Formos Med Assoc, 2006, 105(4): 334-339.
|
[58] |
Shikari H, Antin JH, Dana R. Ocular graft-versus-host disease: a review[J]. Surv Ophthalmol, 2013, 58(3): 233-251.
|
[59] |
Zhang CY, Farooq AV, Harocopos GJ, et al. Corneal perforation in ocular graft-versus-host disease[J]. Am J Ophthalmol Case Rep, 2021, 24: 101224.
|
[60] |
Pfister RR, Murphy GE. Corneal ulceration and perforation associated with Sjögren′s syndrome[J]. Arch Ophthalmol, 1980, 98(1): 89-94.
|
[61] |
Suzuki M, Usui T, Kinoshita N, et al. A case of sterile corneal perforation after bone marrow transplantation[J]. Eye (Lond), 2007, 21(1): 114-116.
|
[62] |
Webster RJ, Slansky HH, Refojo MF, et al. The use of adhesive for the closure of corneal perforations. Report of two cases[J]. Arch Ophthalmol, 1968, 80(6): 705-709.
|
[63] |
Weiss JL, Williams P, Lindstrom RL, et al. The use of tissue adhesive in corneal perforations[J]. Ophthalmology, 1983, 90(6): 610-615.
|
[64] |
Leahey AB, Gottsch JD, Stark WJ. Clinical experience with N-butyl cyanoacrylate (Nexacryl) tissue adhesive[J]. Ophthalmology, 1993, 100(2): 173-180.
|
[65] |
Moschos M, Droutsas D, Boussalis P, et al. Clinical experience with cyanoacrylate tissue adhesive[J]. Doc Ophthalmol, 1996, 93(3): 237-245.
|
[66] |
Yin J, Singh RB, Al KR, et al. Outcomes of cyanoacrylate tissue adhesive application in corneal thinning and perforation[J]. Cornea, 2019, 38(6): 668-673.
|
[67] |
Sharma A, Kaur R, Kumar S, et al. Fibrin glue versus N-butyl-2-cyanoacrylate in corneal perforations[J]. Ophthalmology, 2003, 110(2): 291-298.
|
[68] |
Carlson AN, Wilhelmus KR. Giant papillary conjunctivitis associated with cyanoacrylate glue[J]. Am J Ophthalmol, 1987, 104(4): 437-438.
|
[69] |
Ferry AP, Barnert AH. Granulomatous keratitis resulting from use of cyanoacrylate adhesive for closure of perforated corneal ulcer[J]. Am J Ophthalmol, 1971, 72(3): 538-541.
|
[70] |
Chen HJ, Pires RT, Tseng SC. Amniotic membrane transplantation for severe neurotrophic corneal ulcers[J]. Br J Ophthalmol, 2000, 84(8): 826-833.
|
[71] |
Hanada K, Shimazaki J, Shimmura S, et al. Multilayered amniotic membrane transplantation for severe ulceration of the cornea and sclera[J]. Am J Ophthalmol, 2001, 131(3): 324-331.
|
[72] |
Sanders F, Huang J, Alió DBJ, et al. Amniotic membrane transplantation: structural and biological properties, tissue preparation, application and clinical indications[J]. Eye (Lond), 2024, 38(4): 668-679.
|
[73] |
Deshmukh R, Stevenson LJ, Vajpayee R. Management of corneal perforations: An update[J]. Indian J Ophthalmol, 2020, 68(1): 7-14.
|
[74] |
Chan E, Shah AN, O′Brart DP. "Swiss roll" amniotic membrane technique for the management of corneal perforations[J]. Cornea, 2011, 30(7): 838-841.
|
[75] |
Akle CA, Adinolfi M, Welsh KI, et al. Immunogenicity of human amniotic epithelial cells after transplantation into volunteers[J]. Lancet, 1981, 2(8254): 1003-1005.
|
[76] |
Namba H, Narumi M, Nishi K, et al. "Pleats fold" technique of amniotic membrane transplantation for management of corneal perforations[J]. Cornea, 2014, 33(6): 653-657.
|
[77] |
Mannis MJ, Holland EJ, Gal RL, et al. The effect of donor age on penetrating keratoplasty for endothelial disease: graft survival after 10 years in the Cornea Donor Study[J]. Ophthalmology, 2013, 120(12): 2419-2427.
|
[78] |
Watson SL, Ramsay A, Dart JK, et al. Comparison of deep lamellar keratoplasty and penetrating keratoplasty in patients with keratoconus[J]. Ophthalmology, 2004, 111(9): 1676-1682.
|
[79] |
Cui Y, Xiao X, Hu J. Safety and Efficacy of double lamellar keratoplasty for corneal perforation[J]. Ophthalmol Ther, 2023, 12(2): 1251-1262.
|